Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ARID1A Q456* |
Therapy | Talazoparib |
Indication/Tumor Type | colorectal cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ARID1A Q456* | colorectal cancer | sensitive | Talazoparib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Talzenna (talazoparib) inhibited colony formation and proliferation of a human colorectal cancer cell line harboring ARID1A Q456* in culture and inhibited tumor formation in colorectal cancer xenografts harboring ARID1A Q456* (PMID: 26069190). | 26069190 |
PubMed Id | Reference Title | Details |
---|---|---|
(26069190) | ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. | Full reference... |